NASDAQ:CDXS

Codexis Stock Forecast, Price & News

$25.55
+0.70 (+2.82 %)
(As of 09/21/2021 11:57 AM ET)
Add
Compare
Today's Range
$24.91
$25.62
50-Day Range
$19.65
$27.99
52-Week Range
$11.48
$29.56
Volume11,844 shs
Average Volume514,227 shs
Market Capitalization$1.65 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.29
30 days | 90 days | 365 days | Advanced Chart
Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.


Codexis logo

About Codexis

Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

858th out of 1,352 stocks

Industrial Organic Chemicals Industry

20th out of 23 stocks

Analyst Opinion: 2.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Codexis (NASDAQ:CDXS) Frequently Asked Questions

Is Codexis a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis
or view top-rated stocks.

What stocks does MarketBeat like better than Codexis?

Wall Street analysts have given Codexis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Codexis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Codexis' next earnings date?

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Codexis
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) issued its quarterly earnings results on Thursday, August, 5th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.10. The biotechnology company had revenue of $25.45 million for the quarter, compared to analysts' expectations of $18.04 million. Codexis had a negative net margin of 28.16% and a negative trailing twelve-month return on equity of 15.90%.
View Codexis' earnings history
.

How has Codexis' stock been impacted by Coronavirus (COVID-19)?

Codexis' stock was trading at $10.12 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CDXS stock has increased by 148.4% and is now trading at $25.14.
View which stocks have been most impacted by COVID-19
.

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $98 million-$103 million, compared to the consensus revenue estimate of $88.50 million.

What price target have analysts set for CDXS?

4 brokers have issued 12 month target prices for Codexis' shares. Their forecasts range from $28.00 to $34.00. On average, they anticipate Codexis' stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 20.3% from the stock's current price.
View analysts' price targets for Codexis
or view top-rated stocks among Wall Street analysts.

Who are Codexis' key executives?

Codexis' management team includes the following people:
  • John J. Nicols, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Karl A. Schoene, Senior Vice President-Development & Operations
  • Ross Taylor, Chief Financial Officer & Senior Vice President
  • Stefan Lutz, Senior Vice President-Research
  • Laurie Heilmann, Senior VP-Business Development & Marketing

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees.

Who are some of Codexis' key competitors?

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (10.35%), Baillie Gifford & Co. (10.32%), BlackRock Inc. (8.21%), Nantahala Capital Management LLC (5.97%), Vanguard Group Inc. (4.93%) and William Blair Investment Management LLC (3.63%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis
.

Which major investors are selling Codexis stock?

CDXS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Nantahala Capital Management LLC, Nuveen Asset Management LLC, JPMorgan Chase & Co., Opaleye Management Inc., Bank of New York Mellon Corp, Deutsche Bank AG, and Morgan Stanley. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis
or view top insider-selling stocks.

Which major investors are buying Codexis stock?

CDXS stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., ARK Investment Management LLC, Pier Capital LLC, Dimensional Fund Advisors LP, BlackRock Inc., American Century Companies Inc., AIA Group Ltd, and First Trust Advisors LP.
View insider buying and selling activity for Codexis
or or view top insider-buying stocks.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $25.14.

How much money does Codexis make?

Codexis has a market capitalization of $1.63 billion and generates $69.06 million in revenue each year. The biotechnology company earns $-24,010,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Codexis have?

Codexis employs 181 workers across the globe.

What is Codexis' official website?

The official website for Codexis is www.codexis.com.

Where are Codexis' headquarters?

Codexis is headquartered at 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at (650) 421-8100 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.